Salt Lake City, Utah (April 16, 2014) 4Life executives and distributors gathered over the weekend at the Daemyung Vivaldi Park for recognition, distributor leadership training, and the successful launch of 4Life Transfer Factor Vista™. The rally was attended by more than 500 people. Top distributor leaders in attendance included: Gold International Diamonds Dr. Jase Khyeam, Son Jae Min, Nadzrul Salim, Grace Chun and Lee Sun Woo, Kang Ok Nye, and Hong Suk Eui. Vice President, International Preston Richards, General Manager of Korea Tony Lee and Director, International Yukako Kaiser also attended the event. In addition to motivational presentations by all the Gold International Diamonds in attendance, Preston Richards also presented an update on the market’s performance throughout the past year and celebrated their strong growth. Preston Richards: “It is exciting to see such consistent growth in South Korea. 4Life continues to expand its worldwide presence due to the dedication and strong leadership of so many committed distributors. It is a pleasure to support their success.” With year-over-year sales up 75% in South Korea, the country remains a top-performing 4Life market. 4Life has offices on five continents to serve a global network of independent distributors through science, success, and service.

Salt Lake City, Utah (April 24, 2014) Yesterday, the Direct Selling News (DSN) announced that 4Life has become the 41st largest direct selling company in the world. The DSN Global 100 represents an elite group of the top 100 largest revenue-generating direct selling companies around the world. “Our ongoing growth during the past sixteen years of business as well our steady climb toward the top of the Global 100 best-performing companies are each testaments to the quality and commitment of 4Life business builders in the field. We are excited about what we can accomplish together as 4Life has moved up four spots to #41 in the world,” said President and CEO Steve Tew. When the DSN Global 100 list was first published in 2009, 4Life ranked #71. In 2010, 4Life jumped nine spaces to rank at #62. In 2011 and 2012, 4Life moved seventeen spots to rank at #45. Now, for the 2013–2014 year, the company has secured its position within the top 50 largest companies at #41. 4Life Founder and Chairman of the Board David Lisonbee: “4Life distributors around the world should take great pride in our growth pattern and Direct Selling News Global 100 ranking. It is exciting to watch as the company continues to climb. Bianca and I extend our gratitude for the ongoing commitment of 4Life distributors worldwide.” 4Life has offices on five continents to serve a global network of independent distributors through science, success, and service. For more information: Calvin Jolley Vice President, Communications 4Life Research USA, LLC This e-mail address is being protected from spambots. You need JavaScript enabled to view it

---------- 4LIFE TRANSFER FACTOR® TRI-FACTOR FORMULA PRODUCT DESCRIPTION 4Life Transfer Factor Tri-Factor Formula combines proprietary transfer factors and NanoFactor® molecules extracted from bovine colostrum and chicken egg yolk sources. These molecules contain antigen information which educates, enhances, and helps maintain immune system balance. TECHNICAL DESCRIPTION Transfer factors are molecules that communicate antigenic immunological information intercellularly and from a donor to a recipient. They support immune function through cell mediated immunity. Transfer factors, which carry antigen specific information to which all tested immune cells respond, are produced by mononuclear cells and serve to support and improve immune mediated pathways. Mammalian transfer factors, including those of humans are small molecules between 3,500 and 10,000 daltons. (1; 2) Transfer factors are polypeptides that consist of 40 to 44 amino acids (3) and have a conserved region and a variable region. From a molecular biological standpoint, these two properties are analogous to antibodies; however transfer factor's functions of cell mediated immunity (CMI) and non-specific immunological activity differ almost completely from the functions of antibodies. The molecules that have a molecular weight of less than 3,500 daltons modulate immune response but they do not transfer delayed-type hypersensitivity (DTH). (1) 4Life's transfer factors are sourced from the ultra-filtration of colostrum and from egg yolks. (4; 5) The molecules obtained from the spray dried ultra-filtrate of bovine colostrum are of two classes; the transfer factors present in the ultra-filtrate of ≤10,000 daltons and the nanofraction molecules that are present in the nano-filtrate of ≤3,500 daltons. Transfer factors were first discovered in 1949 by H. Sherwood Lawrence when he demonstrated that CMI could be transferred from one individual to another by way of low molecular weight extracts of white blood cells. Transfer factors could transfer DTH of a specific form from a skin test positive individual to a skin test negative individual who subsequent to the transfer would skin test positive for that antigen. (6) In a subsequent study in 1955 he demonstrated that DTH could be passed serially, first from a skin test positive individual to a test negative individual, who became test positive, then 6 months later from the second individual to another test negative individual who became test positive. (7) At the time antibodies were the focus of immune research and little was known of the importance of DTH and of the involvement of T-cells in immune response. Transfer factors promote wellness via cell mediated immunity. These compounds are components of colostrum, an infant's first meal. They bridge the generational gap by passing cell mediated immunity from mother to infant. BIOLOGICAL AND PHYSIOLOGICAL ACTION Transfer factors' preparations contain more than 200 different moieties of polypeptide molecules with a molecular weight of <10,000 daltons; each moiety potentially having a great number of epitotic variations. These antigen specific factors are synthesized in monocytes and stored in the cytoplasm or on the cell membrane. A significant body of evidence indicates that the primary biological function of transfer factors is to recruit and specifically sensitize previously uncommitted lymphocytes. These sensitized T-lymphocytes initiate the events of cell-mediated immunity, thereby, promoting immunity not only at the site of antigen challenge but also throughout the body. (8) The effect of transfer factors on antigen mediated immunity, via B-cells, is not completely understood; however, a clinical test has reported an increase in particular antibodies, such as IgA and IgG, during transfer factor administration. Clinical studies have demonstrated that transfer factors' unique ability to express DTH and promote cell-mediated immunity can be transferred from a sensitized donor to a non-immune recipient. (1; 9) This antigen specific effect is well documented and is likely produced through activation of the CD3-antigen site of T-cells, increased macrophage activation, and interleukin production—which can also enhance natural killer cell function. (1; 10) Although the exact mechanism of action is unknown, research has shown that transfer factors will bind to antigens. However, the antigen specificity that is “transferred” to recipients is mediated by T-lymphocytes. (3) Current structure function models propose that transfer factors have a variable region and a conserved amino acid region, which determines the antigenic specificity for an estimated 818 epitopes (1) and serves as a binding target for immune cell receptors respectively. (2; 11) These highly conserved regions presumably allow transfer factors to be administered across a species barrier without any loss of potency. In fact, research has demonstrated that bovine transfer factors are structurally analogous to human-derived transfer factors with equivalent physiological activity. This is further supported by several studies, which used transfer factors extracted from bovine lymph nodes and colostrum to confer cell-mediated immunity to specific antigens in animals and human recipients. (12; 13) Although most clinical trials with transfer factors have used parental administration; oral administration has also demonstrated successful transfer of DTH and cell mediated immunity I recipients. (14) Dose response studies, which compare in various routes of administration, have been performed in both human and animals. Results of these experiments refute any arguments that the acidic or enzymatic environment of gastrointestinal tract effects oral administration of transfer factors. (14) CLINICAL AND EXPERIMENTAL STUDIES Natural Killer Cell Activity Peripheral blood mononuclear cells were isolated and pooled from several healthy donors. Sixty thousand cells were added to each well of 96-well microtiter plate. Various immune modulating ingredients, including 4Life Transfer Factor Tri-Factor Formula, were added to select wells on the plate and 48 hour incubation started. At the end of the incubation period 30 thousand K562 cells were added to each well. MTT assay techniques were used to determine the cytotoxic index. The various 4Life Transfer Factor products resulted in cytotoxic indices of 80-98%. By comparison, mononuclear cells incubated with IL-2 for the same 48 hour period produced a cytotoxic index of 88%. CD4 T Helper Cell Research Multiple studies were performed using the FDA-approved diagnostic CD4 T Helper cell assay kit and/or a T Cell Memory (CD8) assay kit under development by the same company. Similar to the NK cell research described above these in vitro studies were preformed on 96-well microtiter plates measuring ATP production via a luciferase-based luminescence reaction. The CD4 assay utilizes PHA-stimulated cells isolated from whole blood via the use of Dynabeads™. An 18 hour incubation of these isolated, stimulated CD4 cells with the 4Life Transfer Factor products has resulted in a modulation of immune cell activity as exhibited by a decrease in ATP production without a negative impact on cell viability. It is hypothesized that this reduction on ATP production is a result of a redirection in immune cell focus, essentially diminishing the distraction induced by the addition of PHA to the microtiter wells. Salivary Secretory IgA-Preliminary Investigation Twenty-four subjects naïve to transfer factor supplementation were enrolled in a small-scale, preliminary test. Twenty-one were included in the final analysis. Salivary samples were collected from each subject weekly at roughly the same time of day and day of the week. Saliva was collected over a 5 minute period via passive drool while subjects chewed on a piece of Parafilm™. The samples were put on ice and then frozen at -70ºC until assay. The commercial Salimetrics™ salivary IgA assay kit was used for analysis. Subjects were given 4Life Transfer Factor Tri-Factor Formula at 2 capsules per day for two weeks and then transitioned to 4Life Transfer Factor RioVida Tri-Factor Formula at 60ml per day for an additional 2 weeks. At the end of the 4 week supplementation period the group showed an average 73% increase in salivary secretory IgA (SIgA) production over their baseline value. Furthermore, none of the 21 subjects showed SIgA production rate less than their baseline value at the end of the test. Wellness Research A study conducted with 30 college students found that either 15 or 30 days of transfer factor administered according to label dose helped them maintain their health. Those that took the product for 30 days showed prolonged health maintenance than those who took it for only 15 days. (15) Longevity Studies Two studies on the effects of 4Life Transfer Factor products on longevity were conducted. An initial, preliminary study was done on mice. This was followed up with a more intricate study on a small group of older men. Groups of 20 mice each were compared in terms of organ weights, serum immune parameters, strength (dynamometer and hanging time), and isoproterenol-induced salivary hyperplasia. One group was injected with 4mg/kg of a product containing transfer factors. The treatment group showed improvements in all the aforementioned parameters. Isoproterenol-induced salivary gland hyperplasia declines with age. This diminished response is thought to be a consequence of decreased lymphoid cellular regulation of somatic tissue growth. The increased hyperplasia seen in the treatment animals approximated that seen in the treatment animals approximated that seen in younger, untreated mice. There were no significant changes noted in height, weight, or rectal temperature between the two groups. (16) Based on the results of this study an additional study was undertaken in 11 older men aged 55-73. Subjects were given 3 capsules per day of a product containing transfer factors 5 days a week for 6 weeks. At the end of the six week study period a determination of biological age using the Kiev method (17; 18) showed a reduction of approximately four years. There were significant improvements in several parameters of cardiovascular function, hearing, balance, vital lung capacity, ability to hold their breath, and some subjective measures. (16) Safety In a study of acute toxicity rats were assessed for fourteen days following a single gavage of 4Life Transfer Factor. Five female SD rats were each gavaged with a dose of 2,000mg/kg. No treatment-related mortalities occurred and there were no clinical signs of toxicity. No significant difference in body weight occurred. No gross lesions were found at necropsy in any of the animals. Thus, acute toxicity is considered to be greater than 2,000mg/kg. Since the discovery of transfer factors in 1949 there have been no reports of allergic reactions (1) or of any side effects resulting from long-term use of 10 years or more. The use of transfer factors is contraindicated in person receiving immunosuppressive therapy, though actual interactions have not been documented. How Supplied 4Life Transfer Factor® can be found in the following products: 4Life Transfer Factor® Tri-Factor® Formula 4Life® Transfer Factor Plus® Tri-Factor® Formula 4Life Transfer Factor® RioVida® Tri-Factor® Formula 4Life Transfer Factor® Chewable Tri-Factor® Formula 4Life Transfer Factor® Classic 4Life Transfer Factor® Immune Spray 4Life Transfer Factor® KBU® 4Life Transfer Factor® Kids 4Life Transfer Factor® Belle Vie® 4Life Transfer Factor® Cardio 4Life Transfer Factor® GluCoach® 4Life Transfer Factor® MalePro® 4Life Transfer Factor® ReCall® 4Life Transfer Factor Vista® 4Life Transfer Factor Renuvo™ 4Life RiteStart® Men 4Life RiteStart® Women REFERENCES Progress in Drug Research. Fundenberg, H. and G. Pizza. 1994, Vol. 42. 309-400. Lawrence, H.S. and W. Borkowsjy. (1-3), 1996, Biotherapy, Vol. 9, pp. 1-5. Kirkpatrick, C.H. 4, 2000, Mol Med, Vol. 6, pp. 332-41. Hennen, W. and D. Lisonbee. s.l. : U.P. Office, Editor., 2002, 4Life Research, LC:USA. Wilson, G. and G. Paddock. s.l. : U.P. Office, Editor., 1989, Amtron, Inc: USA. Lawrence, H.S. 4, 1949, Proc Soc Exp Biol Med, Vol. 71, pp. 516-22. Lawrence, H.S. 2, 1955, J Clin Invest, Vol. 34, pp. 219-30. Levin, A.S., L.E. Spitler, and H.H. Fundenberg. 1973, Annu Rev Med, Vol. 24, pp. 175-208. Fudenberg, H. and H. Fudenberg. 1989, Ann Rev Pharmacol Toxicol, Vol. 29, pp. 475-516. See, D., S. Mason, and R. Roshan. 2, 2002, Immunol Invest, Vol. 31, pp. 137-53. Transfer factor in the age of molecular biology: A review. Dwyer, John M. 1-3, 1996, Biotherapy, Vol. 9, pp. 7-11. Wilson, G.B., R.T. Newell, and N.M. Burdash. 1, 1979, Cell Immunol, Vol. 47, pp. 1-18. Radosevich, J.K., G.H. Scott, and G.B. Olson. 4, 1985, Am J Vet Res, Vol. 46, pp. 875-8. Activities and characteristics of transfer factors. Kirkpatrick, C.H. 1-3, 1996, Biotherapy, Vol. 9, pp. 13-6. in Euromedica Hanover. Chizhov, A. et al. Hanover, Germany : s.n., 2007. in Euromedica Hannover 2004. Klimov, V. and E. Oganova. Hannover, Germany : s.n., 2004. pp. 15-16. Agadzhanian, N., et al. 1996, ATMA. Chebotarev, D. 1984, Annals of Gerontology and Geriatrics. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure of prevent any disease. PRODUCT PHOTO NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size. The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected over dosage, the drug's identity should be verified by chemical analysis.

September 21, 2007 (Salt Lake City, Utah) 4Life Research™, the world leader in Transfer Factor science and immune system support development, announced today the discovery of immune activity in a weight range of molecules significantly smaller than transfer factors. Transfer factors are molecules in a weight class between 3,500 - 12,000 daltons that help the immune system recognize, respond to, and remember outside threats. Although scientists have known that smaller molecules than transfer factors existed within cow colostrum, their significance in terms of immune activity has been unknown until now. In 2005, 4Life Chief Executive Officer David Lisonbee and the Research and Development department began studying these low weight molecules. After two years of research, 4Life clinical findings now indicate that molecules in a weight range between 250 — 3,000 daltons play important regulatory roles in the immune system. 4Life extracted and concentrated these patent-pending nanofraction molecules from cow colostrum for their proprietary NanoFactor™ extract, combining NanoFactor with their exclusive Transfer Factor E-XF™ extract of transfer factors from cow colostrum and chicken egg yolks to produce 4Life Transfer Factor® Tri-Factor™ Formula, the most comprehensive approach to immune system support available today. "I don't know of another company in our category," said 4Life Chief Scientific Officer Calvin McCausland, Ph.D. "In 2004, we were the first company to combine transfer factors from cow colostrum and chicken egg yolks. In 2005, we introduced RioVida®, the world's only transfer factor beverage. Now, the discovery of new immune activity in nanofractions. When it comes to scientific innovation, there's simply no comparison to 4Life." 4Life Transfer Factor, Transfer Factor Plus®, and RioVida are now fortified with the new Tri-Factor Formula. "We're taking Tri-Factor Formula to the world because no other product represents such a unique and indispensable opportunity for a quality life," remarked 4Life President Steve Tew. David Lisonbee: "At the end of the day, our distributors can rest assured that 4Life will stay a good pace ahead of the curve in the areas of science, service, and success."